Multiplex fluorescence quantitative PCR kit for detecting viral myocarditis-related viruses

By developing a multi-fluorescent quantitative PCR kit, using specific primer probes and internal reference genes, the rapid and accurate detection of viral myocarditis-related viruses is achieved, and the problems of long diagnosis time and high cost in the existing technology are solved. Effective treatment options for patients with acute myocarditis.

CN116287468BActive Publication Date: 2024-11-29BEIJING CHUIYANGLIU HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310338775.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-31
Publication Date
2024-11-29
Estimated Expiration
2043-03-31

AI Technical Summary

Technical Problem

There is a lack of effective detection methods for viral myocarditis-related viruses in the prior art, resulting in a long diagnosis time and high cost, making it difficult to provide accurate treatment options for patients with acute myocarditis.

Method used

Develop a multi-fluorescent quantitative PCR kit containing specific primer probes for DNA viruses and RNA viruses, which can simultaneously detect six common viral myocarditis-related viruses, including adenovirus, parvovirus B19, herpes virus 6, and coxa Qivirus B3, influenza A virus H1N1 and EGHO6 are designed using a combination of fluorescence groups and quenching groups, combining internal reference genes to improve the accuracy and efficiency of detection.

Benefits of technology

It significantly reduces the time and cost of viral myocarditis-related virus detection, improves detection efficiency and sensitivity, provides an accurate diagnosis basis for critically ill patients, and helps to choose the appropriate treatment direction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116287468B_ABST
    Figure CN116287468B_ABST
Patent Text Reader

Abstract

The present invention provides a kit for multiplex fluorescence quantitative PCR for detecting viral myocarditis-related viruses. The kit includes a DNA virus primer-probe mixture and an RNA virus primer-probe mixture; the primers in the DNA virus primer-probe mixture include sequences such as SEQ ID NO: 1; the probes in the DNA virus primer-probe mixture include sequences such as SEQ ID NO: 3 connected with a first fluorescent group and a first quenching group; the primers in the RNA virus primer-probe mixture include sequences such as SEQ ID NO: 10; the probes in the RNA virus primer-probe mixture include sequences such as SEQ ID NO: 12 connected with a second fluorescent group and a second quenching group. The kit can solve the problem of long detection time related to viral myocarditis in the prior art and is applicable to the field of biotechnology.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to a multiplex fluorescence quantitative PCR kit for detecting viral myocarditis-related viruses. Background Art

[0002] Viral myocarditis is a complex cardiovascular disease caused by viral infection, resulting in myocardial inflammatory cell infiltration and / or myocardial cell necrosis. It is common in adolescents and is one of the common causes of sudden death in children and young adults. Most patients with viral myocarditis have mild clinical symptoms, and some patients may have further aggravation of their condition or even develop fulminant myocarditis, which causes a heavy burden. In the prior art, there is no definite classification concept or classification method for "viral myocarditis-related viruses". Viral myocarditis may be caused by one virus or a mixed infection of multiple viruses. There are more than 30 viruses that can cause viral myocarditis.

[0003] At present, the methods for detecting viruses include virus isolation and culture, immunological methods and molecular biological methods. Virus isolation and culture is the gold standard for diagnosing viral infection, but the cycle required for virus isolation and culture is long, the positive rate is not high and the operation is complicated. This method is rarely used in clinical practice. The immunological method is based on the principle of antigen-antibody reaction to detect whether the patient carries a certain viral antigen or produces antibodies. However, it takes a period of time after the patient is infected with the virus to detect the corresponding antibodies, which has a certain lag. The sensitivity and specificity of antigen detection are not very ideal due to its methodological limitations. The PCR method can amplify the nucleic acid of the virus millions of times within a few hours under the guidance of specific primers, and has high sensitivity and specificity. Real-time fluorescence quantitative PCR technology has become a common method for virus screening due to its advantages such as real-time detection of results, no need to open the tube, simple and fast, good repeatability and less pollution. It can be used as an effective and rapid means for clinical pathogen diagnosis.

[0004] At present, there are multiple detection kits for enterovirus and multiple detection kits for respiratory virus in the market of my country, but there is no detection kit for viral myocarditis-related viruses, and both enterovirus and respiratory virus can cause the disease, and there is no specific research on which virus or virus combination can cause viral myocarditis in the prior art. It is time-consuming and laborious to use the current enterovirus detection kit and respiratory virus detection kit to screen the pathogen of the disease, which causes a waste of time and experimental cost, and especially brings confusion to the patients in critical and severe conditions to choose the treatment direction. The prior art is difficult to provide a scientific and accurate basis for doctors to decide whether to carry out anti-infection treatment when the condition is dangerous. Therefore, it is urgent to develop a detection reagent that can simultaneously amplify viral myocarditis-related viruses. Summary of the invention

[0005] The main purpose of the present invention is to provide a multiplex fluorescence quantitative PCR kit for detecting viral myocarditis-related viruses, so as to solve the problem of long detection time related to viral myocarditis in the prior art.

[0006] In order to achieve the above object, according to a first aspect of the present invention, a kit for multiplex fluorescence quantitative PCR for detecting viral myocarditis-related viruses is provided, the kit comprising a DNA virus primer-probe mixture and an RNA virus primer-probe mixture; wherein the primers in the DNA virus primer-probe mixture comprise the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 8; the probes in the DNA virus primer-probe mixture comprise SEQ ID NO: 3, SEQ ID NO: 6 and SEQ ID NO: 9 connected with a first fluorescent group and a first quenching group, the 5' or 3' ends of SEQ ID NO: 3, SEQ ID NO: 6 and SEQ ID NO: 9 all carry different first fluorescent groups, and correspondingly, the 3' or 5' ends all carry different first quenching groups that can absorb the fluorescence excited by the first fluorescent group; the primers in the RNA virus primer-probe mixture comprise the following sequences: SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16 and SEQ ID NO: 17; The probes in the RNA virus primer-probe mixture include SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 18 connected with a second fluorescent group and a second quenching group, and the 5' or 3' ends of SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 18 all have different second fluorescent groups, and correspondingly, the 3' or 5' ends all have different second quenching groups that can absorb the fluorescence excited by the second fluorescent group.

[0007] Furthermore, the DNA virus primer-probe mixture and the RNA virus primer-probe mixture both include primers and probes for detecting internal reference genes; the internal reference genes include human gene RNP.

[0008] Furthermore, the DNA virus primer probe mixture and the RNA virus primer probe mixture both include primers and probes for detecting internal reference genes, the primers for detecting internal reference genes include SEQ ID NO: 19 and SEQ ID NO: 20, the probe for detecting internal reference genes includes SEQ ID NO: 21 connected to a third fluorescent group and a third quenching group, the third fluorescent group and the third quenching group are respectively connected to both ends of SEQ ID NO: 21, the third fluorescent group is different from the first fluorescent group and the second fluorescent group, and the third quenching group is different from the first quenching group and the second quenching group.

[0009] Furthermore, the first fluorescent group, the second fluorescent group or the third fluorescent group includes FAM, JOE, Texas CY5, VIC, TET, HEX or ROX; the first quencher group, the second quencher group or the third quencher group includes DABCYL, BHQ1, BHQ2, BHQ3 or TAMRA.

[0010] Furthermore, the probes in the DNA virus primer-probe mixture include: FAM-SEQ ID NO: 3-DABCYL, JOE-SEQ ID NO: 6-BHQ1 and

[0011] Furthermore, the probes in the RNA virus primer-probe mixture include: FAM-SEQ ID NO: 12-DABCYL, JOE-SEQ ID NO: 15-BHQ1 and

[0012] Furthermore, the probe for detecting the internal reference gene includes CY5-SEQ ID NO: 21-BHQ3.

[0013] Furthermore, the kit also includes an enzyme mixture, an RNA virus positive control, a DNA virus positive control, and a negative control; the enzyme mixture includes Taq DNA polymerase and reverse transcriptase; the RNA virus positive control includes a nucleotide sequence having a target fragment of an RNA virus; the DNA virus positive control includes a nucleotide sequence having a target fragment of a DNA virus; the negative control is nuclease-free water; the DNA virus target fragment can specifically bind to the primer in the DNA virus primer-probe mixture; the RNA virus target fragment can specifically bind to the primer in the RNA virus primer-probe mixture.

[0014] Furthermore, the enzyme mixture also includes a buffer, which includes KCl, Tris HCl, MgCl2, TritonX-100 and dNTPs; the dNTPs include dATPs, dGTPs, dCTPs and dTTPs; preferably, the buffer includes 500mM KCl, 100mM Tris HCl pH 9.0 25°C, 15mM MgCl2 and 1% Triton X-100; preferably, the concentration of dNTPs is 0.01mM-1M, preferably 0.1-10mM, and more preferably 0.2mM.

[0015] Furthermore, the kit also includes a nucleic acid extraction reagent.

[0016] By applying the technical solution of the present invention and using the above primers and probes to simultaneously detect the above three DNA viruses or three RNA viruses, the detection time and cost of myocarditis-related viruses can be reduced. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The drawings constituting a part of the present application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0018] Figure 1 The figure shows the result of sensitivity detection of CVB3 according to an embodiment of the present invention.

[0019] Figure 2 The result diagram of sensitivity detection for H1N1 according to an embodiment of the present invention is shown.

[0020] Figure 3 A result diagram of sensitivity detection of ECHO6 according to an embodiment of the present invention is shown.

[0021] Figure 4 The result diagram of sensitivity detection of RNP according to an embodiment of the present invention is shown.

[0022] Figure 5 The result diagram of sensitivity detection of AdV according to an embodiment of the present invention is shown.

[0023] Figure 6 A result diagram of sensitivity detection of PB19 according to an embodiment of the present invention is shown.

[0024] Figure 7 The result diagram of sensitivity detection of HHV6 according to an embodiment of the present invention is shown. DETAILED DESCRIPTION

[0025] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present invention will be described in detail below in conjunction with the embodiments.

[0026] In the prior art, there is no exact concept or virus classification method for "viruses associated with viral myocarditis". Various viruses such as herpes simplex virus type 1 and type 2, cytomegalovirus, Epstein-Barr virus, coxsackie virus B, coxsackie virus A, adenovirus C, influenza A virus, influenza B virus, hepatitis B virus, hepatitis C virus, measles virus, rubella virus, boca virus (BOCA) and their different subtypes and genotypes may cause myocarditis. However, in clinical diagnosis, it is not feasible to test all related viruses, whether based on time cost or test cost.

[0027] The design of the kit disclosed in this application is derived from the needs of clinical diagnosis. The inventor has repeatedly encountered critically ill patients in clinical work who are at a critical juncture where they urgently need to choose anti-inflammatory or thrombolytic treatment. It has been difficult to determine whether they are patients with acute viral myocarditis and the need for diagnosis for a long time. In particular, for acute myocarditis, it is impossible to distinguish whether the organisms in the heart cavity are inflammatory substances through CT or MRI images. For critically ill patients with such symptoms, a kit is developed that can perform experimental medical tests on in vitro samples such as blood, body fluids, and feces and determine or exclude viral infection factors. At the cost of minimal medical examination of the patient's physical damage, the patient's condition can be quickly judged to maximize the patient's interests. Through a large number of clinical practices and data analysis, combined with the correlation between viruses and myocarditis, the frequency of occurrence of viruses in clinical practice (especially in my country), and other factors, the inventor creatively screened out 6 viruses for inclusion in the group, which can cover the most common types of viruses that cause viral myocarditis in my country, including DNA viruses and RNA viruses, among which DNA viruses include adenovirus (AdV), parvovirus B19 (PB19) and herpes virus 6 (HHV6); RNA viruses include coxsackievirus B3 (CVB3), influenza A virus H1N1 and echovirus ECHO6. Testing the above 6 viruses can determine to the greatest extent whether the subject is a patient with viral myocarditis, and it also has lower time and test costs compared to testing all the above related viruses.

[0028] As mentioned in the background technology, currently, molecular diagnosis for viruses is mainly performed in PCR laboratories through 6 independent diagnostic kits. The time required for each virus specimen processing plus laboratory diagnosis is about 3 hours, and the 6 virus kits take about 10-18 hours. However, there have been no reports and market applications of multiple PCR diagnostic kits for viral myocarditis-related viruses. Due to the 6 independent experiments, the cost of manpower and reagents also increases significantly, which increases the economic burden on patients and also brings confusion and interference to the choice of emergency or ICU doctors whether to choose antiviral treatment.

[0029] Therefore, in this application, the inventors have attempted to develop a multiplex fluorescent quantitative PCR kit that can accelerate the detection of related viruses, and proposed a series of protection schemes for this application. It can greatly reduce the blind clinical medication and etiology diagnosis of patients in the clinic. The above-mentioned kit uses modern genetic engineering methods to advance the etiology diagnosis process to before medication, which can improve the welfare of the subjects. Specimen testing selects samples such as blood, urine and stool from patients, which are easy to collect, do not cause unnecessary open line damage to patients, and do not require local tissue puncture or cardiac catheter sampling; and through the 10n amplification sensitivity characteristics of PCR technology, the window time when the virus appears in the main excreta of the human body is captured.

[0030] In a first typical embodiment of the present application, a kit for multiplex fluorescence quantitative PCR for detecting viral myocarditis-related viruses is provided, the kit comprising a DNA virus primer-probe mixture and an RNA virus primer-probe mixture; wherein the primers in the DNA virus primer-probe mixture comprise the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 8; the probes in the DNA virus primer-probe mixture comprise SEQ ID NO: 3, SEQ ID NO: 6 and SEQ ID NO: 9 connected with a first fluorescent group and a first quenching group, SEQ ID NO: 3, SEQ ID NO: 6 and SEQ ID NO: 9 have a first fluorescent group at the 5' or 3' end, and the first fluorescent groups connected to SEQ ID NO: 3, SEQ ID NO: 6 and SEQ ID NO: 9 are different; accordingly, the 3' or 5' end both have different first quenching groups that can absorb the fluorescence excited by the first fluorescent group; the primers in the RNA virus primer-probe mixture comprise the following sequences: SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12 NO: 13, SEQ ID NO: 14, SEQ ID NO: 16 and SEQ ID NO: 17; the probes in the RNA virus primer probe mixture include SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 18 connected with a second fluorescent group and a second quenching group, and the 5' or 3' ends of SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 18 all have different second fluorescent groups, and accordingly, the 3' or 5' ends all have different second quenching groups that can absorb the fluorescence excited by the second fluorescent group.

[0031] The above-mentioned viral myocarditis-related viruses include DNA viruses and RNA viruses. Among them, DNA viruses include adenovirus (AdV), parvovirus B19 (PB19) and herpes virus 6 (HHV6); RNA viruses include coxsackievirus B3 (CVB3), influenza A virus H1N1 and echovirus ECHO6. The kit includes a DNA virus primer probe mixture and an RNA virus primer probe mixture; the DNA virus primer probe mixture includes primers and probe sequences for detecting AdV adenovirus, parvovirus B19 and herpes virus 6. The fluorescent group and quenching group on the above-mentioned probe can be flexibly located at the 5' end and 3' end of the nucleotide sequence.

[0032] The primer and probe sequences used to detect AdV adenovirus are as follows:

[0033] Upstream primer AdV-F: SEQ ID NO: 1: 5'-TGACCACCGAYCGTAGCCAG-3',

[0034] Downstream primer AdV-R: SEQ ID NO: 2: 5'-CCCACGGCCAGKGTGTACC-3',

[0035] Specific probe AdV-P: first fluorescent group / first quenching group-SEQ ID NO: 3-first quenching group / first fluorescent group,

[0036] SEQ ID NO: 3: 5'-TCAACGGGCACGAAGCGCAAC-3'.

[0037] The primer and probe sequences used to detect parvovirus B19 (PB19) are as follows:

[0038] Upstream primer PB19-F: SEQ ID NO: 4: 5'-CTCATCACYCCAGGCGC-3',

[0039] Downstream primer PB19-R: SEQ ID NO: 5: 5'-GAGGAAACTGRGCTTCCGACA-3',

[0040] Specific probe PB19-P: first fluorescent group / first quenching group-SEQ ID NO: 6-first quenching group / first fluorescent group:

[0041] SEQ ID NO: 6: 5'-TCCCCGGGACCAGTTCAGGAGAAT-3'.

[0042] The primer and probe sequences used to detect herpes virus 6 (HHV6) are as follows:

[0043] Upstream primer HHV6-F: SEQ ID NO: 7: 5'-GTCTTCCGTGACTATTCCR-3',

[0044] Downstream primer HHV6-R: SEQ ID NO: 8: 5'-CCTAATGTCAAACTTATGCTG-3',

[0045] Specific probe HHV6-P: first fluorescent group / first quenching group-SEQ ID NO: 9-first quenching group / first fluorescent group:

[0046] SEQ ID NO: 9: 5'-ATCCCGTTAATCCCATCCT-3'.

[0047] The first fluorescent group and the first quenching group used in the above three specific probes are different.

[0048] The RNA virus primer-probe mixture includes primers and probes for detecting Coxsackie virus B3, influenza A virus H1N1 and ECHO6 virus.

[0049] The primer and probe sequences used to detect Coxsackievirus B3 (CVB3) are as follows:

[0050] Upstream primer CVB3-F: SEQ ID NO: 10: 5'-CTGTTCACCTCACCGTTTGT-3',

[0051] Downstream primer CVB3-R: SEQ ID NO: 11: 5'-TTGCCAAGGCTCTGCTATCT-3',

[0052] Specific probe CVB3-P: second fluorescent group / second quenching group-SEQ ID NO: 12-second quenching group / second fluorescent group:

[0053] SEQ ID NO: 12: 5'-CTTGGCATCGACCAATGCAGGA-3'.

[0054] The primer and probe sequences used to detect influenza A virus H1N1 are as follows:

[0055] Upstream primer H1N1-F: SEQ ID NO: 13: 5'-GGTCACGCAAAGAACAATAGGGA-3',

[0056] Downstream primer H1N1-R: SEQ ID NO: 14: 5'-CAGGTGTTGCGATAGCCCTT-3',

[0057] Specific probe H1N1-P: second fluorescent group / second quenching group-SEQ ID NO: 15-second quenching group / second fluorescent group:

[0058] SEQ ID NO: 15: 5'-ACCAAAGATGCAGAGAGAGGCAAGT-3'.

[0059] The primer and probe sequences used to detect ECHO6 virus are as follows:

[0060] Upstream primer ECHO6-F: SEQ ID NO: 16: 5'-YCATGTTAGATCAGAATCGTCC-3',

[0061] Downstream primer ECHO6-R: SEQ ID NO: 17: 5'-CAKYTTRTCTGGGGTDTCRTC-3',

[0062] Specific probe ECHO6-P: second fluorescent group / second quenching group-SEQ ID NO: 18-second quenching group / second fluorescent group,

[0063] SEQ ID NO: 18: 5'-ATCTGCCTGTGTWTACATYGTGRR-3'.

[0064] The second fluorescent group and the second quenching group used in the above three specific probes are different.

[0065] In the above nucleotide sequence, Y represents C or T, K represents G or T, R represents A or G, W represents A or T, and D represents A, G or T.

[0066] The design of the primers in the above kit is not a simple mixture or combination of primers. First, different DNA and RNA viruses have different procedures for processing virus specimens. RNA viruses need to be reverse transcribed when performing RT-PCR, while DNA viruses do not need such treatment, so they are divided into DNA group and RNA group. In the DNA group or RNA group, the amplification primer design of each virus must be specific. The optimal length of the amplified fragment is 100-300bp, so the selection of specific gene fragments is the first step. Secondly, different viruses will have similar or complementary sequence fragments in the same reaction system, and there will also be related homologous complementary sequences between primers, resulting in the appearance of primer dimers or hairpin structures, which will lead to the failure of amplifying virus-specific fragments. Thirdly, in the PCR process, the annealing temperature is required to be 40-60°C, but after multiple primers are mixed, the annealing temperature is difficult to control, which requires that while the primers and substrates are fully complementary to ensure the effectiveness of amplification, the annealing temperature cannot be controlled below 60°C due to the G+C base content not being too high. With each additional virus detection reagent (including primers and probes) in the test kit, the difficulty and interference factors theoretically increase exponentially, so it is necessary to consider achieving a delicate balance, which is to ensure that the number of viruses included in the group (6 types) is sufficient to meet the clinical diagnosis needs of most patients, while also making a balanced decision without reducing the accuracy, sensitivity and anti-interference factors of the diagnostic reagents.

[0067] Therefore, in the design of primers, first of all, we must ensure the specificity of effectively amplifying the target gene fragment, secondly, we must ensure that there is no cross-recombination between different viruses during amplification, and thirdly, we must ensure that there is no related binding amplification between primers. As the number of viruses to be detected increases, the difficulty will increase exponentially. It is by no means a simple combination or integration.

[0068] In a preferred embodiment, the DNA virus primer-probe mixture and the RNA virus primer-probe mixture both include primers and probes for detecting internal reference genes; the internal reference genes include human gene RNP.

[0069] The introduction of human internal standard genes will also increase the difficulty and balance selection of the above-mentioned PCR reaction, but it enables the reagents to identify the quality and properties of the specimens submitted for inspection, avoiding deviations or human errors that occur when clinical specimens are collected, and thus whether the internal standard gene is amplified can serve as an important support for judging the reliability of the amplification results.

[0070] However, the selection of which human gene to use as the internal reference gene is based on the characteristics of the experimental specimens. It should be selected from samples such as blood, urine, and stool that are relatively easy to detect, and at the same time, it does not need to be over-expressed to avoid competing with the virus to be detected in the reagent for other reagents or ions in the reaction system, thereby avoiding the problem of false negatives in the test results. In the early stages of viral infection, the viral load in the body is not high. If the content of human genes such as β-actin or GAPDH is too high, it will compete with the detected virus for PCR amplification raw materials, making it impossible for viruses with low viral loads to be fully amplified, resulting in false negatives. In addition, the present invention selects RNP as the internal standard, and reduces the content of primers required for RNP by adjusting to reduce the interference of the internal standard product on the target gene, thereby ensuring the amplification of the target gene.

[0071] In a preferred embodiment, the DNA virus primer-probe mixture and the RNA virus primer-probe mixture both include primers and probes for detecting internal reference genes. The primers for detecting internal reference genes include SEQ ID NO: 19 and SEQ ID NO: 20, and the probe for detecting the internal reference gene includes SEQ ID NO: 21 connected to a third fluorescent group and a third quenching group. The third fluorescent group and the third quenching group are respectively connected to both ends of SEQ ID NO: 21, the third fluorescent group is different from the first fluorescent group and the second fluorescent group, and the third quenching group is different from the first quenching group and the second quenching group.

[0072] Primers used to detect the internal reference gene include:

[0073] Upstream primer RNP-F: SEQ ID NO: 19: 5'-AGATTTGGACCTGCGAGCG-3',

[0074] Downstream primer RNP-R: SEQ ID NO: 20: 5'-GAGCGGCTGTCTCCACAAGT-3'.

[0075] The probe for detecting the internal reference gene includes a specific probe RNP-P: third fluorescent group / third quenching group-SEQ ID NO: 21-third quenching group / third fluorescent group,

[0076] SEQ ID NO: 21: TTCTGACCTGAAGGCTCTGCGCG.

[0077] In a preferred embodiment, the first fluorescent group, the second fluorescent group or the third fluorescent group includes but is not limited to FAM (6-carboxyfluorescein), JOE (6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein succinimidyl ester), Texas (sulfurhodamine), CY5 (cyanine 5), VIC (VIC fluorescent dye), TET (tetrachloro-6-carboxyfluorescein), HEX (hexachloro-6-methylfluorescein) or ROX (carboxy-X-rhodamine); the first quenching group, the second quenching group or the third quenching group include but are not limited to DABCYL (4-(4-dimethylaminophenylazo)benzoic acid), BHQ1 (BHQ-1 carboxylic acid), BHQ2 (BHQ-2 carboxylic acid), BHQ3 (BHQ-3 carboxylic acid) or TAMRA (6-carboxytetramethylrhodamine).

[0078] The fluorescent group and the quenching group can be arbitrarily selected from the fluorescent groups and quenching groups in the prior art, including but not limited to the above groups and combinations of groups. In the kit, the first fluorescent group and the third fluorescent group cannot be the same, and the second fluorescent group and the third fluorescent group cannot be the same, so as to avoid confusion between the internal reference signal and the signal of the virus to be detected during detection. Since the probes corresponding to the first fluorescent group and the second fluorescent group are not mixed, the selection of the first fluorescent group and the second fluorescent group can be the same.

[0079] In a preferred embodiment, the probes in the DNA virus primer-probe mixture include: FAM-SEQ ID NO: 3-DABCYL, JOE-SEQ ID NO: 6-BHQ1 and

[0080] In a preferred embodiment, the probes in the RNA virus primer-probe mixture include: FAM-SEQ ID NO: 12-DABCYL, JOE-SEQ ID NO: 15-BHQ1 and

[0081] In a preferred embodiment, the probe for detecting the internal reference gene includes CY5-SEQ ID NO: 21-BHQ3.

[0082] In a preferred embodiment, the kit also includes an enzyme mixture, an RNA virus positive control, a DNA virus positive control, and a negative control; the enzyme mixture includes Taq DNA polymerase and reverse transcriptase; the RNA virus positive control includes a nucleotide sequence having a target fragment of an RNA virus; the DNA virus positive control includes a nucleotide sequence having a target fragment of a DNA virus; the negative control is nuclease-free water; the DNA virus target fragment can specifically bind to the primer in the DNA virus primer-probe mixture; the RNA virus target fragment can specifically bind to the primer in the RNA virus primer-probe mixture.

[0083] In a preferred embodiment, the enzyme mixture also includes a buffer, which includes KCl, Tris HCl, MgCl2, Triton X-100 and dNTPs; dNTPs include dATPs, dGTPs, dCTPs and dTTPs; preferably, the buffer includes 500mM KCl, 100mM Tris HCl pH 9.0 25°C, 15mM MgCl2 and 1% Triton X-100.

[0084] In the above buffer, Taq DNA polymerase and reverse transcriptase can play corresponding roles to achieve amplification of DNA samples, or reverse transcription and amplification of RNA samples.

[0085] In a preferred embodiment, the kit further comprises a nucleic acid extraction reagent.

[0086] The nucleic acid extraction reagent includes components and materials used for nucleic acid extraction in the prior art, optionally including but not limited to sodium dodecyl sulfate, ethylphenyl polyethylene glycol, weak cationic chelating resin or magnetic beads, etc.

[0087] The above-mentioned kit can provide an objective scientific and technological basis for the selection of treatment direction for clinical critically ill patients. In the development process of this kit, by proposing the interpretation of viral myocarditis-related viruses and taking clinical needs as the main problem target, the inclusion of 6 viruses can cover the vast majority of clinical diagnostic needs; the amplification sensitivity advantage of the multiplex fluorescence quantitative PCR method is fully utilized, and interference factors are avoided by cleverly and carefully designing primers to the maximum extent; specimens such as blood and urine are easy to obtain, reducing unnecessary medical damage to patient specimen collection; the introduction of NPR internal standard design can monitor specimen quality and avoid competition with viral specimens in the test object for PCR reaction system materials.

[0088] The above-mentioned test kit can be used to determine the main medication direction for critically ill patients, whether they need anti-infection support or thrombolytic therapy such as intracardiac biologics.

[0089] In a second typical embodiment of the present application, a use of the above-mentioned kit in detecting viral myocarditis is provided.

[0090] The above applications include but are not limited to using the above kit to detect respiratory samples, urine samples or fecal samples, and respiratory samples include but are not limited to pharyngeal swabs, nasal swabs, sputum, bronchoscopic aspirate and / or alveolar lavage fluid. The above applications include applications for in vitro samples and non-diagnostic purposes, and also include methods for diagnosing or identifying viral myocarditis in subjects.

[0091] The kit used in the examples of the present application comprises two tubes of primer-probe reaction solutions: an RNA tube containing CVB3, H1N1, ECHO6 and RNP primer pairs and specific probes; and a DNA tube containing AdV, PB19, HHV6 and RNP primer pairs and specific probes.

[0092] The specific fluorescent labeling groups of the kit of the present invention include but are not limited to FAM, JOE, Texas Or the fluorescent labeling groups in the existing technology such as CY5, which can be adapted to fluorescent quantitative PCR instruments such as ABI Prism 7500 and SLAN 96P.

[0093] The six viral myocarditis-related virus multiplex fluorescence quantitative PCR detection kit provided by the present invention needs to be stored at -20°C to minimize repeated freezing and thawing; the RNA primer probe reaction solution and the DNA primer probe reaction solution need to be stored in the dark.

[0094] The method of using the kit of the present invention is as follows: positive control and negative control need to be set for each sample detection, and the positive control and negative control do not need to participate in the extraction and directly participate in the nucleic acid amplification step.

[0095] Respiratory sample pretreatment and nucleic acid extraction: The extraction reagents can be used with commercial kits for nucleic acid extraction:

[0096] 1) Swab type: shake the virus preservation tube containing virus preservation solution for 1 minute, let it stand for 10 minutes, then aspirate the virus preservation solution for extraction.

[0097] 2) Sputum, bronchoscopically aspirated fluid, and alveolar lavage fluid: Add an appropriate amount of 4% NaOH solution according to the viscosity of the sample, shake thoroughly and mix, and liquefy at room temperature for 30 minutes. The sample is completely liquefied when there is no solid or stringy state, and can be used for extraction.

[0098] For fecal sample pretreatment and nucleic acid extraction, commercial kits can be used for nucleic acid extraction: Take an appropriate amount of fecal specimen and add it to 1 mL of PBS to prepare a 10% fecal suspension. Shake and mix three times for 10 seconds each time, then let stand at room temperature for 10 minutes and centrifuge at 8000 r / min for 5 minutes. Aspirate the supernatant for nucleic acid extraction.

[0099] For the extraction of nucleic acid from whole blood samples, take the "Nucleic Acid Extraction or Purification Reagent" produced by Shengxiang Biotechnology Co., Ltd. as an example: take 800μL of the mixed whole blood sample and add it to 1mL of red blood cell lysis buffer, centrifuge at 12000rpm / min for 1min, and discard the supernatant; add 1mL of red blood cell lysis buffer to the precipitate, mix thoroughly, centrifuge at 12000rpm / min for 3min, and discard the supernatant; then add 1mL of normal saline, centrifuge directly at 12000rpm / min for 10min, and discard the supernatant; add 400μL of nucleic acid releaser to the precipitate, shake and mix, keep it at 75℃ for 10min, and then centrifuge it instantly to participate in amplification.

[0100] Nucleic acid amplification: The kit of the present invention needs to be restored to room temperature before use, and the enzyme mixture cannot be shaken. The total reaction volume is 25μL, and the extracted nucleic acid of the sample to be tested, the positive control and the negative control nucleic acid are used as templates. Add 19μL of RNA virus primer probe mixture to 4 tubes of the eight-tube series, add 19μL of DNA virus primer probe mixture to the other 4 tubes, add 1μL of enzyme mixture to each tube, and then add 5μL of template to each tube, cover the lid and centrifuge instantly. Detection was performed on the ABI Prism 7500 and SLAN 96P fluorescence quantitative PCR instruments, and the probe detection mode was set according to the above-mentioned fluorescent labeling group and the corresponding fluorescence quenching group. When using the ABI Prism 7500 fluorescence quantitative PCR instrument for detection, select "NONE" for the Reference Dye option. The nucleic acid amplification reaction parameter settings are shown in Table 1:

[0101] Table 1:

[0102]

[0103] The results are shown in Table 2:

[0104] Table 2:

[0105] Result judgment RNA virus tube DNA virus tube Negative No Ct value or Ct value is 0 or Ct>37 No Ct value or Ct value is 0 or Ct>37 Positive 0<Ct≤34 0<Ct≤30 gray area 34<Ct≤37 30<Ct≤37

[0106] The above results must be interpreted based on the premise that the internal standard RNP is amplified and the Ct value is ≤37, otherwise the result interpretation is invalid.

[0107] The kit of the present invention adopts a one-step fluorescence quantitative PCR detection method, and can detect six viruses related to viral myocarditis at one time in two independent PCR reaction tubes. The method is simple and easy to operate. The internal standard adopts a human internal standard, which is amplified together with the target virus nucleic acid, which can not only monitor the sampling quality, but also facilitate the interpretation of the sample detection results. Three RNA viruses and three DNA viruses are amplified under the same reaction conditions, which is more convenient, faster and more cost-effective than the single-plex fluorescence PCR detection method.

[0108] The beneficial effects of the present application will be further explained in detail below in conjunction with specific embodiments.

[0109] Example 1: Establishment of a multiplex fluorescence quantitative PCR detection method for six viruses associated with viral myocarditis

[0110] Viral myocarditis is one of the common causes of sudden death in children and young adults, and its incidence rate has gradually increased in recent years. Most acute viral myocarditis patients have mild symptoms, but a small number of patients may be transferred to chronic, progress to dilated cardiomyopathy, eventually leading to death or needing heart transplantation. Viral myocarditis can be caused by one or more viral mixed infections, and it has been found that the morbidity of viral myocarditis is relevant with nearly 30 kinds of viral infections, including some enteroviruses, respiratory viruses and human immunodeficiency virus and hepatitis virus etc. However, CVB3, ECHO6, influenza A virus H1N1, AdV, PB19 and HHV6 account for 60% of the viral myocarditis virus spectrum. The present embodiment mainly detects six kinds of viruses at CVB3, ECHO6, influenza A virus (H1N1 subtype), AdV, PB19 and HHV6.

[0111] Solution design:

[0112] 1. Primer and probe design

[0113] Multiple gene sequences covering domestic and foreign CVB3, ECHO6, H1N1, AdV, PB19 and HHV6 viruses were downloaded from the NCBI gene library. BioEdit software was used to compare the homology and determine the conserved regions of the above viral genomes. Oligo7 software was used to design highly specific primers and Taqman probes in its conserved regions. Both primer and probe sequences were verified by Blast and had good specificity. The primer and probe sequences of human internal standard RNP refer to the nucleotide sequence published by the US Centers for Disease Control and Prevention. The final selected primer and probe sequences after design are described below. The primers and probes were commissioned to be synthesized by Invitrogen (Shanghai) Trading Co., Ltd. The positive control is a recombinant plasmid consisting of the target fragment carrying the pUC57 plasmid, which was commissioned to be synthesized by Qingke Biotechnology Co., Ltd.

[0114] Primer and probe sequences:

[0115] Upstream primer AdV-F: SEQ ID NO: 1: 5'-TGACCACCGAYCGTAGCCAG-3',

[0116] Downstream primer AdV-R: SEQ ID NO: 2: 5'-CCCACGGCCAGKGTGTACC-3',

[0117] Upstream primer PB19-F: SEQ ID NO: 4: 5'-CTCATCACYCCAGGCGC-3',

[0118] Downstream primer PB19-R: SEQ ID NO: 5: 5'-GAGGAAACTGRGCTTCCGACA-3',

[0119] Upstream primer HHV6-F: SEQ ID NO: 7: 5'-GTCTTCCGTGACTATTCCR-3',

[0120] Downstream primer HHV6-R: SEQ ID NO: 8: 5'-CCTAATGTCAAACTTATGCTG-3',

[0121] Upstream primer CVB3-F: SEQ ID NO: 10: 5'-CTGTTCACCTCACCGTTTGT-3',

[0122] Downstream primer CVB3-R: SEQ ID NO: 11: 5'-TTGCCAAGGCTCTGCTATCT-3',

[0123] Upstream primer H1N1-F: SEQ ID NO: 13: 5'-GGTCACGCAAAGAACAATAGGGA-3',

[0124] Downstream primer H1N1-R: SEQ ID NO: 14: 5'-CAGGTGTTGCGATAGCCCTT-3',

[0125] Upstream primer ECHO6-F: SEQ ID NO: 16: 5'-YCATGTTAGATCAGAATCGTCC-3',

[0126] Downstream primer ECHO6-R: SEQ ID NO: 17: 5'-CAKYTTRTCTGGGGTDTCRTC-3',

[0127] Upstream primer RNP-F: SEQ ID NO: 19: 5'-AGATTTGGACCTGCGAGCG-3',

[0128] Downstream primer RNP-R: SEQ ID NO: 20: 5'-GAGCGGCTGTCTCCACAAGT-3'.

[0129] Specific probe AdV-P: FAM-SEQ ID NO: 3-DABCYL,

[0130] Specific probe PB19-P: JOE-SEQ ID NO: 6-BHQ1:

[0131] Specific probe HHV6-P:

[0132] Specific probe CVB3-P: FAM-SEQ ID NO: 12-DABCYL:

[0133] Specific probe H1N1-P:JOE-SEQ ID NO:15-BHQ1:

[0134] Specific probe ECHO6-P:

[0135] The probes used to detect the internal reference gene include the specific probe RNP-P:CY5-SEQ ID NO:21-BHQ3.

[0136] The structure of the above probe takes the specific probe AdV-P as an example, FAM-SEQ ID NO: 3-DABCYL, which means that a FAM fluorescent group is connected to one end of SEQ ID NO: 3, and a DABCYL quenching group is connected to the other end.

[0137] 2. Optimization of reaction system and reaction conditions

[0138] According to the commercialized AgPath-ID TM The amount of each primer probe was optimized according to the recommended amount in the One-stepRT-PCR Kit manual. The total reaction volume after optimization was 25 μL, including 19 μL of RNA virus primer probe mixture and 19 μL of DNA virus primer probe mixture. The above two reaction solutions needed to be centrifuged before use, 1 μL of enzyme mixture, and 5 μL of template. The detection was performed on the ABI Prism 7500 fluorescence quantitative PCR instrument (reference dye option selected "NONE"), and the reaction parameter settings were shown in Table 3:

[0139] Table 3:

[0140]

[0141] 3. Result judgment:

[0142] Select FAM as the fluorescence detection channel. For JOE and CY5 fluorescence, the baseline adjustment is to take the average fluorescence signal of 3-15 cycles, and the threshold is set so that the threshold line just exceeds the highest point of the negative control. If the sample shows a typical amplification curve, it is judged as positive. If there is no typical amplification curve, it is judged as negative.

[0143] The sensitivity of the kit of the present invention for detecting six viruses related to viral myocarditis and internal references includes:

[0144] CVB3, 1.2752×10 4 copies / mL; H1N1, 9.792×10 3 copies / mL; ECHO6, 1.19×10 4 copies / mL; RNP, 1.2712×10 4 copies / mL; AdV, 1.2049×10 5 copies / mL; PB19, 1.2508×10 5 copies / mL; HHV6, 9.556×10 4 copies / mL, copies is the copy number.

[0145] The sensitivity test results for CVB3, H1N1, ECHO6, RNP, AdV, PB19 and HHV6 are shown in the figure below. Figure 1 , Figure 2 , Figure 3 , Figure 4 , Figure 5 , Figure 6 and Figure 7 shown.

[0146] △Rn in the figure is a commonly used evaluation index for RT-PCR sensitivity. The calculation method of △Rn is Rn (Normalized reporter) minus the baseline value, where: Rn is the ratio of the fluorescence appearance value of the reporter dye divided by the fluorescence of the reference dye; △Rn changes with the number of PCR cycles. Generally, △Rn is automatically calculated by the PCR instrument and plotted into a graph. The number above the baseline in the figure is the value of the threshold line (baseline), which is used to determine the CT value in real-time quantitative analysis and also indirectly affects the △Rn level.

[0147] Example 2

[0148] A sample for respiratory adenovirus testing, the sample type is bronchoscopic aspirate fluid.

[0149] Nucleic acid extraction: according to the viscosity of the sample, add an appropriate amount of 4% NaOH solution, shake and mix thoroughly, liquefy at room temperature for 30 minutes, and liquefy completely when there is no solid or stringy state, and set aside. Extract nucleic acid according to the instructions of "Nucleic Acid Extraction or Purification Reagent" produced by Changchun Zhiang Biotechnology Co., Ltd.

[0150] Amplification reagent preparation:

[0151] Using the above kit, vortex the reagents in the box for tens of seconds (the enzyme does not need to be shaken), and then centrifuge instantly. Calculate the number of amplification reagents to be prepared (n = number of samples + 2 tubes of control). The preparation of the reaction system for each person is shown in Table 4:

[0152] Table 4:

[0153]

[0154]

[0155] Calculate the usage amount of each of the above reagents, mix thoroughly, centrifuge instantly, and dispense 20 μL into n RNA virus and DNA virus PCR amplification tubes.

[0156] Add sample:

[0157] Pipette 5 μL template (extracted nucleic acid from the sample to be tested, negative control, and positive control) and add them to the RNA virus and DNA virus PCR amplification tubes respectively, centrifuge them instantly, and set aside (if there are bubbles, tap the amplification tube to eliminate them and then centrifuge them instantly).

[0158] Amplification:

[0159] After instant centrifugation, the PCR amplification tubes were transferred to the fully automatic fluorescent quantitative PCR detector (ABI Prism7500) for amplification detection. The amplification program is shown in Table 5:

[0160] Table 5:

[0161]

[0162] The results are shown in Table 6.

[0163] Table 6:

[0164]

[0165] From the above description, it can be seen that the above-mentioned embodiments of the present invention achieve the following technical effects: using the primers and probes in the above-mentioned kit, it is possible to simultaneously detect the above-mentioned three DNA viruses and three RNA viruses related to viral myocarditis, thereby reducing the detection time and detection cost of myocarditis-related viruses, and greatly shortening the detection time limit related to viral myocarditis in the prior art, while improving efficiency and sensitivity, and taking into account reducing false positive interference problems, for critically ill patients with complex conditions who urgently need medication control, a highly sensitive detection reagent and method is provided, thereby determining whether to use infectious treatment or intracardiac thrombolytic treatment such as biologics in subsequent treatment, and providing an important basis for critically ill patients to choose the direction of treatment, such as whether to undergo antiviral treatment.

[0166] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A multiplex fluorescence quantitative PCR kit for detecting viral myocarditis-related viruses, characterized in that: The kit includes a DNA virus primer probe mixture and an RNA virus primer probe mixture; Wherein, the DNA virus primer probe mixture includes primers with the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 8; The probes in the DNA virus primer-probe mixture include probes with sequences shown in SEQ ID NO: 3, SEQ ID NO: 6 and SEQ ID NO: 9 connected with a first fluorescent group and a first quenching group, The 5' or 3' end of SEQ ID NO: 3, SEQ ID NO: 6 and SEQ ID NO: 9 all carry different first fluorescent groups, and correspondingly, the 3' or 5' end all carry different first quenching groups that can absorb the fluorescence excited by the first fluorescent groups; The RNA virus primer-probe mixture includes primers with the following sequences: SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16 and SEQ ID NO: 17; The probes in the RNA virus primer-probe mixture include probes with sequences shown in SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 18 connected to a second fluorescent group and a second quenching group, The 5' or 3' end of SEQ ID NO: 12, SEQ ID NO: 15 and SEQ ID NO: 18 all carry different second fluorescent groups, and correspondingly, the 3' or 5' end all carry different second quenching groups that can absorb the fluorescence excited by the second fluorescent groups.

2. The kit according to claim 1, characterized in that The DNA virus primer-probe mixture and the RNA virus primer-probe mixture both include primers and probes for detecting internal reference genes; The internal reference gene includes human gene RNP.

3. The kit according to claim 2, characterized in that The DNA virus primer-probe mixture and the RNA virus primer-probe mixture both include primers and probes for detecting an internal reference gene. The primer sequences for detecting the internal reference gene are shown in SEQ ID NO: 19 and SEQ ID NO:

20. The probe for detecting the internal reference gene is connected to a third fluorescent group and a third quenching group and has a sequence as shown in SEQ ID NO:

21. The third fluorescent group and the third quenching group are connected to both ends of SEQ ID NO: 21, respectively. The third fluorescent group is different from both the first fluorescent group and the second fluorescent group, The third quencher group is different from both the first quencher group and the second quencher group.

4. The kit according to claim 3, characterized in that The first fluorescent group, the second fluorescent group or the third fluorescent group comprises FAM, JOE, Texas Red®, CY5, VIC, TET, HEX or ROX; The first quencher group, the second quencher group or the third quencher group includes DABCYL, BHQ1, BHQ2, BHQ3 or TAMRA.

5. The kit according to claim 1, characterized in that The probes in the DNA virus primer-probe mixture include: FAM - SEQ ID NO: 3 - DABCYL, JOE - SEQ ID NO: 6 - BHQ1 and Texas Red® - SEQID NO: 9 - BHQ2.

6. The kit according to claim 1, characterized in that The probes in the RNA virus primer-probe mixture include: FAM - SEQ ID NO: 12 - DABCYL, JOE - SEQ ID NO: 15 - BHQ1 and Texas Red® - SEQID NO: 18 - BHQ2.

7. The kit according to claim 3, characterized in that The probe for detecting the internal reference gene includes CY5-SEQ ID NO: 21-BHQ3.

8. The kit according to any one of claims 1 to 7, characterized in that The kit also includes an enzyme mixture, an RNA virus positive control, a DNA virus positive control, and a negative control; The enzyme mixture includes Taq DNA polymerase and reverse transcriptase; The RNA virus positive control comprises a nucleotide sequence having a target fragment of the RNA virus; The DNA virus positive control substance includes a nucleotide sequence having a target fragment of the DNA virus; The negative control is nuclease-free water; The target DNA virus fragment can specifically bind to the primer in the DNA virus primer-probe mixture; The RNA virus target fragment can specifically bind to the primer in the RNA virus primer-probe mixture.

9. The kit according to claim 8, characterized in that The enzyme mixture also includes a buffer comprising KCl, Tris HCl, MgCl2, Triton X-100 and dNTPs.

10. The kit according to claim 9, characterized in that The dNTPs include dATPs, dGTPs, dCTPs and dTTPs.

11. The kit according to claim 9, characterized in that The buffer consisted of 500 mM KCl, 100 mM Tris HCl pH 9.0 at 25°C, 15 mM MgCl2, and 1% Triton X-100.

12. The kit according to claim 9, characterized in that The concentration of the dNTPs is 0.01 mM-1M.

13. The kit according to claim 12, characterized in that The concentration of the dNTPs is 0.1-10 mM.

14. The kit according to claim 13, characterized in that The concentration of the dNTPs was 0.2 mM.

15. The kit according to any one of claims 1 to 7, characterized in that The kit also includes a nucleic acid extraction reagent.

Citation Information

Patent Citations

  • Parvovirus B19 nucleic acid quantitative detection kit

    CN111270008A

  • Differential diagnostics and therapy of virally induced heart muscle disease

    WO2007096199A2